Ultragenyx Pharmaceutical (RARE) Finished Goods (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Finished Goods data on file, last reported at $22.0 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $22.0 million, down 4.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.0 million (down 4.84% YoY), and the FY2025 annual result was $25.0 million, up 8.7% from the prior year.
• Finished Goods declined to $22.0 million in Q1 2026 per RARE's latest filing, from $25.0 million in the prior quarter.
• Over five years, Finished Goods peaked at $26.7 million in Q2 2025 and troughed at $4.9 million in Q2 2022.
• A 5-year average of $15.8 million and a median of $14.9 million in 2024 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2022 and 2023: Finished Goods retreated 13.08% in 2022, then surged 107.99% in 2023.
• A 5-year view of Finished Goods shows it stood at $9.3 million in 2022, then surged by 62.82% to $15.1 million in 2023, then surged by 52.22% to $23.0 million in 2024, then climbed by 8.7% to $25.0 million in 2025, then declined by 12.0% to $22.0 million in 2026.
• Business Quant data shows RARE's Finished Goods at $22.0 million in Q1 2026, $25.0 million in Q4 2025, and $23.0 million in Q3 2025.